Klebsiella pneumoniae Infections - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Klebsiella pneumoniae Infections - Pipeline Review, H2 2018’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections

- The report reviews pipeline therapeutics for Klebsiella pneumoniae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Klebsiella pneumoniae Infections therapeutics and enlists all their major and minor projects

- The report assesses Klebsiella pneumoniae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Klebsiella pneumoniae Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ABAC Therapeutics SA

Acies Bio doo

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

BB200 LLC

C3J Therapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International ...

ABAC Therapeutics SA

Acies Bio doo

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

BB200 LLC

C3J Therapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

Kyorin Pharmaceutical Co Ltd

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Nosopharm SAS

Novartis AG

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Plc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Klebsiella pneumoniae Infections - Overview 5

Klebsiella pneumoniae Infections - Therapeutics Development 6

Klebsiella pneumoniae Infections - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 4

Klebsiella pneumoniae Infections - Overview 5

Klebsiella pneumoniae Infections - Therapeutics Development 6

Klebsiella pneumoniae Infections - Therapeutics Assessment 15

Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development 23

Klebsiella pneumoniae Infections - Drug Profiles 36

Klebsiella pneumoniae Infections - Dormant Projects 108

Klebsiella pneumoniae Infections - Discontinued Products 110

Klebsiella pneumoniae Infections - Product Development Milestones 111

Appendix 120

List of Tables

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 14 ...

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 14

Number of Products under Development by Universities/Institutes, H2 2018 16

Products under Development by Companies, H2 2018 17

Products under Development by Universities/Institutes, H2 2018 20

Number of Products by Stage and Target, H2 2018 22

Number of Products by Stage and Mechanism of Action, H2 2018 24

Number of Products by Stage and Route of Administration, H2 2018 26

Number of Products by Stage and Molecule Type, H2 2018 28

Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, H2 2018 29

Klebsiella pneumoniae Infections - Pipeline by Acies Bio doo, H2 2018 29

Klebsiella pneumoniae Infections - Pipeline by AmpliPhi Biosciences Corp, H2 2018 30

Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H2 2018 30

Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, H2 2018 30

Klebsiella pneumoniae Infections - Pipeline by C3J Therapeutics Inc, H2 2018 31

Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, H2 2018 31

Klebsiella pneumoniae Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2018 32

Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H2 2018 32

Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H2 2018 32

Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018 33

Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018 33

Klebsiella pneumoniae Infections - Pipeline by LegoChem Biosciences Inc, H2 2018 34

Klebsiella pneumoniae Infections - Pipeline by Meiji Seika Pharma Co Ltd, H2 2018 34

Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H2 2018 35

Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, H2 2018 35

Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H2 2018 35

Klebsiella pneumoniae Infections - Pipeline by Novartis AG, H2 2018 36

Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H2 2018 36

Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc, H2 2018 37

Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H2 2018 37

Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H2 2018 38

Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, H2 2018 38

Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, H2 2018 39

Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Plc, H2 2018 39

Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H2 2018 40

Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018 40

Klebsiella pneumoniae Infections - Pipeline by Vaxdyn SL, H2 2018 41

Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Center, H2 2018 41

Klebsiella pneumoniae Infections - Dormant Projects, H2 2018 114

Klebsiella pneumoniae Infections - Discontinued Products, H2 2018 116

List of Figures

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 13 ...

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number of Products under Development by Universities/Institutes, H2 2018 16

Number of Products by Top 10 Targets, H2 2018 21

Number of Products by Stage and Top 10 Targets, H2 2018 21

Number of Products by Top 10 Mechanism of Actions, H2 2018 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 23

Number of Products by Routes of Administration, H2 2018 25

Number of Products by Stage and Routes of Administration, H2 2018 25

Number of Products by Top 10 Molecule Types, H2 2018 27

Number of Products by Stage and Top 10 Molecule Types, H2 2018 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports